Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
15 oct 2015 - 07:30
Statutory name
Galapagos NV
Title
Galapagos advances triple combination therapy in cystic fibrosis
Comments
- GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro
- Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to address 80% of mutations in the CF population
- Multiple series of C2 correctors identified, each with unique mode of action
- GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy
Date last update: 05 April 2026